<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648241</url>
  </required_header>
  <id_info>
    <org_study_id>B9371039</org_study_id>
    <nct_id>NCT04648241</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older</brief_title>
  <official_title>A PHASE 3, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF A TICK-BORNE ENCEPHALITIS VACCINE IN HEALTHY JAPANESE PARTICIPANTS 1 YEAR OF AGE AND OLDER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to provide safety and immunogenicity data in Japanese&#xD;
      participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion who are seropositive (achieving neutralization test [NT] titer ≥1:10) in 16 years of age and older.</measure>
    <time_frame>4 weeks after third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The proportion who are seropositive (achieving NT titer ≥1:10) in 1 to &lt;16 years old.</measure>
    <time_frame>4 weeks after third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting local reactions.</measure>
    <time_frame>7 days after each vaccination.</time_frame>
    <description>Prompted local reactions after each dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting systemic events.</measure>
    <time_frame>7 days after each vaccination.</time_frame>
    <description>Prompted systemic events after each dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting AEs.</measure>
    <time_frame>1 month after each vaccination.</time_frame>
    <description>AEs within 1months after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of participants reporting SAEs.</measure>
    <time_frame>Up to approximately 15 months.</time_frame>
    <description>SAEs throughout the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion who are seropositive (achieving NT titer ≥1:10) in 16 years of age and older.</measure>
    <time_frame>4 weeks after the second dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMTs in 16 years of age and older.</measure>
    <time_frame>4 weeks after the second and 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMFRs as compared to baseline in 16 years of age and older.</measure>
    <time_frame>4 weeks after the second and 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMFR 4 weeks after the third dose as compared to 4 weeks after the second dose in 16 years of age and older.</measure>
    <time_frame>4 weeks after the second dose to 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion who are seropositive (achieving NT titer ≥1:10) in 1 to &lt;16 years old.</measure>
    <time_frame>4 weeks after the second dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMTs in 1 to &lt;16 years old.</measure>
    <time_frame>4 weeks after the second and 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMFRs as compared to baseline in 1 to &lt;16 years old.</measure>
    <time_frame>4 weeks after the second and 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT GMFR 4 weeks after the third dose as compared to 4 weeks after the second dose in 1 to &lt;16 years old.</measure>
    <time_frame>4 weeks after the second dose to 4 weeks after the third dose.</time_frame>
    <description>TBEV-neutralizing antibody titers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Tick-Borne Encephalitis</condition>
  <arm_group>
    <arm_group_label>≥16 Years Old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBE vaccine 0.5 mL (intramuscular injection).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 to &lt;16 Years Old</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TBE vaccine 0.25ｍL (intramuscular injection).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBE vaccine 0.5 mL</intervention_name>
    <description>TBE vaccine 0.5 mL (intramuscular injection).</description>
    <arm_group_label>≥16 Years Old</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBE vaccine 0.25 mL</intervention_name>
    <description>TBE vaccine 0.25 mL (intramuscular injection).</description>
    <arm_group_label>1 to &lt;16 Years Old</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese male or female participants ≥1 years old at Visit 1.&#xD;
&#xD;
          -  Participants and/or a legally acceptable representative/parent/legal guardian are&#xD;
             willing and able to comply with all scheduled visits, vaccination plan, and other&#xD;
             study procedures including completion of the e-diary for 7 days for participants after&#xD;
             each of 3 vaccinations.&#xD;
&#xD;
          -  Participants and/or a legally acceptable representative/parent/legal guardian must be&#xD;
             able to be contacted by telephone during study participation.&#xD;
&#xD;
          -  Participants and/or a legally acceptable representative/parent/legal guardian are&#xD;
             capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major known congenital malformation or serious chronic disorder.&#xD;
&#xD;
          -  Known history of TBEV infection.&#xD;
&#xD;
          -  Known history of other flavivirus infection (eg, dengue fever, yellow fever, JEV, West&#xD;
             Nile virus).&#xD;
&#xD;
          -  Known history of infection with HIV, HCV, or HBV.&#xD;
&#xD;
          -  Immunocompromised participants with known or suspected immunodeficiency.&#xD;
&#xD;
          -  History of autoimmune disease or an active autoimmune disease requiring therapeutic&#xD;
             intervention.&#xD;
&#xD;
          -  Previous vaccination with any licensed or investigational TBE vaccine, or planned&#xD;
             receipt of other flavivirus vaccines apart from JEV vaccine (eg, yellow fever, dengue&#xD;
             fever) during the study. Administration of JEV vaccine is prohibited during&#xD;
             participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Co. LTA PS Clinic</name>
      <address>
        <city>Fukuoka,</city>
        <state>Fukuoka</state>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azuma kodomo katei clinic</name>
      <address>
        <city>Ebetsu Shi</city>
        <state>Hokkaido</state>
        <zip>069-0816</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watanabe Pediatric Allergy Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>006-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohigesenseino Kodomo Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>062-0907</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUZURAN Children's Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>063-0841</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens clinic of Kose</name>
      <address>
        <city>Kofu-city</city>
        <state>Yamanashi</state>
        <zip>400-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B9371039</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis, Tick-Borne</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

